Ulcerative Colitis Market in 8MM – Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)

Publication ⇒ Nov-23

Delivery Time ⇒ 5-7 Business Days

Report Code ⇒PBCHC202-8M-TR

License Type (Price in USD)

Ulcerative Colitis Market – Report Overview

Pacific Business Consulting’s “Ulcerative Colitis Market in 8MM – Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)” report offers a comprehensive understanding of Ulcerative Colitis, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Eight Major Markets (8MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and China.

The ulcerative colitis (UC) market size across the Eight Major Markets (8MM) was valued at US$7.8 billion in 2022 and is expected to grow at a Compound Annual Growth Rate (CAGR) of more than 2% during the forecast period from 2022 to 2030. Ulcerative Colitis is an idiopathic inflammatory bowel condition that affects the colonic mucosa, characterized clinically by symptoms such as diarrhea, stomach discomfort, pain, and hematochezia.

Approximately 40% to 60% of patients present with mild to moderate or severe symptoms at initial diagnosis, and around 15% of mild patients may eventually progress to the moderate to severe patient group. The symptoms of UC can vary among individuals and may include diarrhea with blood or pus, abdominal pain and cramping, passing blood with stool, and urgency to defecate.

UC can occur at any age, with most people being diagnosed in their mid-thirties. Both men and women are equally likely to be affected, but older men are more likely to be diagnosed than older women. Treatment for ulcerative colitis is complex and may involve medication, dietary and nutritional changes, and sometimes surgical procedures to repair or remove affected portions of the gastrointestinal tract.

Currently, various types of medications are used for UC treatment, including immunomodulators, aminosalicylates, corticosteroids, S1P modulators, Janus kinase inhibitors, biologic therapies, and others. The treatment landscape is evolving with the emergence of new therapies. In the U.S., approved treatments for moderate to severe ulcerative colitis include interleukin antagonists (ustekinumab, mirikizumab), anti-TNFa agents (adalimumab, infliximab, golimumab), anti-integrin agents (vedolizumab), S1P receptor modulator (ozanimod), and JAK inhibitors (tofacitinib, upadacitinib).

Drivers of growth in the UC market include increased prevalence rates, the approval and launch of pipeline products, high treatment rates across the 8MM, and a high unmet need for safe and efficacious therapies. Major players in the ulcerative colitis market include AbbVie, Boehringer Ingelheim, EA Pharma, Abivax, Bristol Myers Squib, Eli Lilly, Galapagos, Gilead, Protagonist Therapeutics, Takeda, InDex Pharmaceuticals, Janssen, and Pfizer.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Ulcerative Colitis market. It also delves into the analysis of present and prospective market competition within the global Ulcerative Colitis market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

  • Develop your business strategies by gaining insights into the trends that shape and drive the Ulcerative Colitis market across the 8MM (Eight Major Markets).
  • Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 8MM Ulcerative Colitis market.
  • Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
  • Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

Please note that detailed pipeline analysis can be provided along with the standard scope to assist you in developing and designing your in-licensing and out-licensing strategies. This includes a review of pipeline products and technologies, along with identifying companies with the most robust pipeline.

  1. Executive Summary: Ulcerative Colitis
    • Global Market Outlook: Ulcerative Colitis
  2. Competitive Intelligence Analysis: Ulcerative Colitis
  3. Therapeutic Sector SWOT
  4. Technology Roadmap Analysis: Ulcerative Colitis
  5. Market Background
    • Drivers
    • Restraints
    • Opportunity
    • Key Market Trends
    • Key Unmet Needs
  6. Disease Overview: Ulcerative Colitis
    • Disease Etiology
    • Pathophysiology
    • Risk Factors
    • Treatment Algorithm
  7. Ulcerative Colitis: Key Marketed Products Profile – Major Approved Products
    • Product Profile
    • Regulatory Milestones
    • Safety and Efficacy
    • Clinical Development
  8. Ulcerative Colitis: Promising Pipeline Candidates – Major Products in Late Stage of Development
    • Product Description
    • Safety and Efficacy
    • Research and Development
  9. Regulatory Landscape
  10. Ulcerative Colitis: Eight Major Market (8MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  11. S. Ulcerative Colitis – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  12. K. Ulcerative Colitis – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  13. Germany Ulcerative Colitis – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  14. France Ulcerative Colitis – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  15. Italy Ulcerative Colitis – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  16. Spain Ulcerative Colitis – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  17. Japan Ulcerative Colitis – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  18. China Ulcerative Colitis – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
  19. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

  1. Assumptions and Acronyms Used
  2. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
  3. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, and China

Copyrights and Disclaimer

Customize Reports As Per Your Needs

Don’t see what you’re looking for? Get a report tailored to your specific requirements. Customize your report now!

Have A Question?

We are happy to assist you.

Phone:+919599779105
Email:info@pacificbusinessconsulting.com